| Literature DB >> 33844109 |
Xiaoqi Wei1, Hanchuan Chen2, Zhebin You1, Jie Yang1, Haoming He2, Chen He2, Weiping Zheng1, Kaiyang Lin3, Feng Jiang4.
Abstract
BACKGROUND: This study aimed to investigate the connection between malnutrition evaluated by the Controlling Nutritional Status (CONUT) score and the risk of contrast-associated acute kidney injury (CA-AKI) in elderly patients who underwent percutaneous coronary intervention (PCI).Entities:
Keywords: Contrast-associated acute kidney injury; Controlling Nutritional Status (CONUT) score; Elderly; Malnutrition; Percutaneous coronary intervention
Mesh:
Substances:
Year: 2021 PMID: 33844109 PMCID: PMC8357678 DOI: 10.1007/s10157-021-02061-4
Source DB: PubMed Journal: Clin Exp Nephrol ISSN: 1342-1751 Impact factor: 2.801
Fig. 1Study population
Baseline characteristics of patients in different groups classified by CONUT score
| Variables | Normal | Mild | Moderate-severe | |
|---|---|---|---|---|
| Age, years | 78.89 3.34 | 79.09 3.55 | 80.66 4.48 | < 0.001 |
| Sex, female, | 194 (38.19%) | 152 (21.47%) | 20 (21.74%) | < 0.001 |
| Systolic blood pressure, mmHg | 138.24 23.40 | 134.44 22.05 | 127.30 20.62 | < 0.001 |
| Diastolic blood pressure, mmHg | 72.27 12.43 | 71.55 23.58 | 67.94 12.71 | 0.155 |
| Hypertension, | 377 (74.2%) | 552 (78.0%) | 74 (80.4%) | 0.211 |
| Diabetes, | 175 (34.5%) | 260 (36.7%) | 37 (40.2%) | 0.498 |
| Smoker, | 140 (30.2%) | 229 (36.2%) | 27 (32.9%) | 0.114 |
| Atrial fibrillation, | 62 (12.2%) | 102 (14.4%) | 12 (13.0%) | 0.536 |
| Emergency PCI, | 68 (13.4%) | 109 (15.4%) | 25 (27.2%) | 0.003 |
| Myocardial infarction, | 191 (37.6%) | 304 (42.9%) | 67 (72.8%) | < 0.001 |
| Perioperative hypotension, | 45 (8.9%) | 76 (10.7%) | 18 (19.6%) | 0.009 |
| Serum creatinine, μmol/L | 84.46 28.86 | 89.69 30.60 | 108.09 85.05 | < 0.001 |
| WBC, × 109/L | 7.74 2.44 | 7.39 2.66 | 7.78 3.45 | 0.049 |
| lymphocyte, × 109/L | 2.04 0.58 | 1.51 0.58 | 1.02 0.40 | < 0.001 |
| HGB, g/L | 132.1514.92 | 129.34 16.13 | 117.07 20.98 | < 0.001 |
| HCT | 0.39 0.04 | 0.38 0.04 | 0.35 0.06 | < 0.001 |
| ALB, g/L | 40.73 3.33 | 39.46 4.04 | 33.27 4.36 | < 0.001 |
| Cholesterol, mg/dL | 189.88 39.51 | 43.70 32.91 | 121.97 27.93 | < 0.001 |
| Glucose, mmol/L | 7.12 2.97 | 7.23 3.08 | 9.02 4.82 | < 0.001 |
| Uric acid, μmol/L | 380.68 102.36 | 377.61 108.65 | 354.82 121.18 | 0.103 |
| eGFR, mL/min/1.73 m2 | 80.37 24.70 | 78.93 25.36 | 70.17 25.31 | 0.002 |
| eGFR < 60 mL/min/1.73 m2, | 100 (19.7%) | 156 (22.0%) | 31 (33.7%) | 0.011 |
| Urine PH | 6.27 0.71 | 6.29 0.74 | 6.25 0.72 | 0.885 |
| Anemia, | 181 (35.6%) | 331 (46.8%) | 65 (70.7%) | < 0.001 |
| Hyperuricemia, | 203 (40.0%) | 243 (34.3%) | 26 (28.3%) | 0.035 |
| Statin, | 498 (98.0%) | 699 (98.7%) | 91 (98.9%) | 0.637 |
| ACEI/ARB, | 405 (79.7%) | 586 (82.8%) | 71 (77.2%) | 0.242 |
| Antiplatelet, | 498 (98.0%) | 695 (98.2%) | 89 (96.7%) | 0.598 |
| Metformin, | 73 (14.4%) | 87 (12.3%) | 12 (11.0%) | 0.539 |
| Multi-vessel coronary artery disease, | 403 (79.3%) | 569 (80.4%) | 78 (84.8%) | 0.479 |
| Number of diseased vessels, | 2.32 ± 0.82 | 2.38 ± 0.82 | 2.45 ± 0.75 | 0.254 |
| Number of stents, | 1.59 ± 0.75 | 1.68 ± 0.80 | 1.65 ± 0.74 | 0.160 |
| Iso-osmolar contrast media use, | 172 (33.9%) | 267 (37.7%) | 34 (37.0%) | 0.381 |
| Volume of contrast media, mL | 177.07 52.39 | 177.70 57.76 | 179.78 54.41 | 0.909 |
| Contrast volume > 200 mL, | 88 (17.3%) | 128 (18.1%) | 19 (20.7%) | 0.741 |
WBC white blood cell, HGB hemoglobin, HCT hematocrit, ALB albumin, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
Baseline characteristics between non CA-AKI group and CA-AKI group
| Non CA-AKI | CA-AKI | ||
|---|---|---|---|
| Age, years | 79.0 53.49 | 79.70 4.06 | 0.121 |
| Sex, female, | 311 (27.0%) | 55 (34.8%) | 0.052 |
| Systolic blood pressure, mmHg | 135.96 22.21 | 131.64 25.47 | 0.078 |
| Diastolic blood pressure, mmHg | 71.66 19.93 | 71.03 13.88 | 0.723 |
| Hypertension, | 877 (76.3%) | 126 (79.8%) | 0.384 |
| Emergency PCI, | 153 (13.3%) | 49 (31.0%) | < 0.001 |
| Diabetes, | 590 (51.3%) | 109 (69.0%) | < 0.001 |
| Atrial fibrillation, | 142 (12.4%) | 34 (21.5%) | 0.002 |
| Smoker, | 352 (34.0%) | 44 (30.4%) | 0.430 |
| MI, | 455 (39.6%) | 107 (67.7%) | < 0.001 |
| Perioperative hypotension, | 96 (8.3%) | 43 (27.2%) | < 0.001 |
| Statin, | 1132 (98.4%) | 156 (98.7%) | 1.000 |
| Antiplatelet agents, | 1129 (98.3%) | 153 (96.8%) | 0.231 |
| ACEI/ARB, | 931 (81.0%) | 123 (77.9%) | 0.413 |
| Metformin, | 150 (13.0%) | 21 (13.3%) | 1.000 |
| Serum creatinine, μmol/L | 88.09 29.88 | 95.27 69.28 | 0.597 |
| WBC, × 109/L | 7.39 2.48 | 8.72 3.42 | < 0.001 |
| Lymphocyte, × 109/L | 1.70 0.64 | 1.54 0.69 | 0.005 |
| HGB, g/L | 129.96 16.06 | 126.71 19.03 | 0.099 |
| HCT | 0.38 0.05 | 0.37 0.05 | 0.073 |
| ALB, g/L | 39.78 4.15 | 37.57 4.21 | < 0.001 |
| Cholesterol, mg/dL | 159.85 43.50 | 161.98 38.06 | 0.187 |
| Glucose, mmol/L | 7.17 3.07 | 8.38 4.01 | < 0.001 |
| eGFR, mL/min/1.73 m2 | 78.93 23.75 | 78.47 34.06 | 0.247 |
| eGFR < 60 mL/min/1.73 m2, | 242(21.0%) | 45 (28.5%) | 0.044 |
| Urine PH | 6.29 0.72 | 6.22 0.80 | 0.090 |
| CONUT score | < 0.001 | ||
| 0–1, | 453 (39.4%) | 55 (34.8%) | |
| 2–4, | 630 (54.8%) | 78 (49.4%) | |
| ≥ 5, | 67 (5.8%) | 25 (15.8%) | |
| Anemia, | 267 (23.2%) | 48 (30.4%) | 0.061 |
| Hyperuricemia, | 395 (34.4%) | 77 (48.7%) | 0.001 |
| Contrast volume, mL | 176.14 55.91 | 188.23 51.01 | 0.006 |
| Contrast volume ≥ 200 mL, | 190 (16.5%) | 45 (28.5%) | 0.003 |
| Iso-osmolar contrast media use, | 416 (36.2%) | 57 (36.1%) | 1.000 |
| Number of stents, | 1.65 0.78 | 1.58 0.73 | 0.388 |
| Multi-vessel coronary artery disease, | 915 (79.57%) | 135 (85.44%) | 0.102 |
MI myocardial infarction, PCI percutaneous coronary intervention, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate, ALB albumin, WBC white blood cell, HGB hemoglobin, HCT hematocrit
Associations between CONUT score and CA-AKI
| Participants, | Events, | Rate,% | Model 1* | Model 2† | |||
|---|---|---|---|---|---|---|---|
| CONUT score 0–1 | 508 | 55 | 10.83 | 0.40 (0.23–0.72) | 0.002 | 0.48 (0.26–0.89) | 0.02 |
| CONUT score 2–4 | 708 | 78 | 11.02 | 0.40 (0.23–0.70) | 0.001 | 0.46 (0.26–0.82) | 0.009 |
| CONUT score ≥ 5 | 92 | 25 | 27.17 | Reference | – | Reference | – |
*Model 1 adjusted for age, anemia, diabetes, contrast media volume > 200 ml, eGFR < 60 ml/(min·1.73 m2). †Model 2 adjusted for variables in model 1 plus atrial fibrillation, emergency PCI, MI, WBC, glucose, hyperuricemia, perioperative hypotension. CI confidence interval, OR odds ratio
Fig. 2Subgroup analysis of the effect of CONUT score on CA-AKI incidence in the matched cohort
Fig. 3Incidence rate of CA-AKI in patients with various combination of CONUT score and anemia